摘要
目的观察依达拉奉联合阿加曲班治疗急性脑梗死（ACI）的临床效果。方法选取2013年1月~2015年1月在我科住院的124例ACI患者,按照随机数字表法分为对照组和治疗组,各62例。对照组给予阿加曲班治疗,治疗组给予阿加曲班联合依达拉奉治疗,疗程均为14 d。测定两组患者治疗前后神经功能缺损评分、血清超敏C反应蛋白（hs-CRP）及同型半胱氨酸（Hcy）水平,并进行分析。结果治疗组的治疗总有效率为91.94%,显著高于对照组的74.19%,差异有统计学意义（P〈0.05）。治疗后,两组的神经功能缺损程度评分低于治疗前,且治疗组显著低于对照组（P〈0.05）;治疗后,两组患者的血清hs-CRP、Hcy水平均显著低于治疗前,治疗组低于对照组,两组差异有统计学意义（P〈0.05）。结论依达拉奉联合阿加曲班可以降低血清hs-CRP和Hcy水平,能有效改善ACI患者的神经功能缺损程度。
Objective To observe the clinical efficacy of edaravone combined with argatroban in the treatment of acute cerebral infarction（ACI）. Methods 124 patients with ACI admitted into our hospital from January 2013 to January 2015 were selected and evenly divided into the control group and the treatment group according to the random number table method,62 cases in each group.The control group was given edaravone treatment,treatment group was given argatroban combined with argatroban treatment.The treatment course was 14 days.The neurological impairment scores and serum high-sensitivity C-reactive protein（hs-CRP） and homocysteine（Hcy） levels in two groups before and after treatment was measured and analyzed. Results The treatment total effective rate in treatment group was 91.94%,which was significantly higher than 74.19% of control group,the difference was significant（P0.05）.After treatment,the neurological impairment scores in two groups than that of before treatment,and treatment group was significantly lower than that of control group（P0.05）.After treatment,the hs-CRP and Hcy levels in two group reduced significantly compared to those before treatment,and treatment group was lower than that of control group,the difference was significant between two groups（P0.05）. Conclusion Edaravone combined with argatroban can reduce the serum hs-CRP and Hcy levels,and can effectively improve the neurological impairment degree of patients with ACI.
出处
《中国当代医药》
2015年第28期125-127,共3页
China Modern Medicine
关键词
依达拉奉
阿加曲班
急性脑梗死
超敏C反应蛋白
同型半胱氨酸
Edaravone
Argatroban
Acute cerebral infarction
High-sensitivity C-reactive protein
Homocysteine
